Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin vs teicoplanin to prevent donor-derived gram-positive infections after liver transplantation
ChiCTR2100041926Phase 4Recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jan 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of daptomycin in Gram-positive bacterial infection and Staphylococcus aureus infection (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Culture results and Postoperative graft function. Started Jan 2021; status: recruiting.
02
Drugs
daptomycin
03
Conditions
Gram-positive bacterial infectionStaphylococcus aureus infection
Beyond the preview
Go deeper on ChiCTR2100041926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041926.